Telitacicept Add-On Boosts Renal Response in Proliferative Lupus Nephritis
This real-world comparative analysis suggests dual B-cell activating factor/proliferation-inducing ligand (BAFF/APRIL) blockade with telitacicept added to standard care raises complete renal response rates and accelerates glucocorticoid tapering in proliferative lupus nephritis, informing induction regimen selection.
Telitacicept enhances renal response in lupus nephritis.
Telitacicept combined with standard care improves renal outcomes for patients with proliferative lupus nephritis, potentially enhancing current treatment protocols. At week 24, patients on telitacicept had higher complete renal response (67.9% vs 39.3%, p=0.004) and partial renal response rates (83.9% vs 67.9%, p=0.023) compared to controls. This study indicates that telitacicept may offer a more effective induction therapy for proliferative lupus nephritis, although these findings require validation in broader clinical trials. Telitacicept significantly boosts renal response rates in proliferative lupus nephritis, offering potential for reduced glucocorticoid use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Tian T, Zhang A, Liu X, Wu P, Li N, Zeng L, Liu J, Qin L, Zeng J
Citation:Tian T, Zhang A, Liu X, et al. Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. Lupus science & medicine. 2026;13(2). doi:10.1136/lupus-2026-002191